Scaling Spray-dried Dispersions For Commercial Success: Scale, Capacity, Supply

Plastic Components And Systems Used In Pharmaceutical Manufacturing

Building a Global Manufacturing Network: "Dual-Sourcing" Commercial Strategies

Precision At Scale: Optimizing Cell-Free DNA Manufacturing For mRNA Vaccines

Developing Custom GMP Lipids: A Patient-Driven Partnership

Smarter Lead Selection And Faster Representative Material

Design Verification Done Right: Smarter Strategies For Prefillable Syringes

IND In As Little As 6 Months: Now Beyond mAbs - Accelerating Bispecifics, Fc-Fusions And High-Concentration Biologics To The Clinic

Scaling Cell And Gene Therapy Manufacturing

CESS Technology

Discovering A Unique Multimillion Euro Nanotechnology Facility

Rapid, Material-Sparing Feasibility Screening For Hot Melt Extrusion

Formulation Of Crystalline Nanoparticles Enabling Superior Drug Load

Accelerating Clinical Development: Modern Tools In Process Chemistry

Spray Dried Biologics For Pulmonary Dosage Forms

Formulating Better ASDs And mAbs: Advances In Applied Nanotechnology

Considerations For Large-Scale API Production

Addressing Raw Material Handling Challenges By Dry Granulation

Cambrex Scientist Spotlight: Ross McLellan

How To Safely Handle Your Antibody Drug Conjugate

Dramatic Reduction Of Solvent Usage In Pharmaceutical Spray Drying

CRISPR Genome Editing Solutions From Discovery To Clinic

Bio4C ProcessPad™ Product Overview

Tailored CMC Solutions That Meet Needs Of Novel Molecular Biologic Formats

Biopharmaceuticals Development And Manufacturing: Wide-Ranging Expertise And Vertically Integrated Service

Accelerate Your AAV Journey To IND And Beyond

Viral Safety Of Biologics: What's Changing With The ICH Q5A Revision?

Meet The Experts: Part 3 - Chemometrics And Model Building

How Biosafety Assurance Can Be Both Rapid And Purposeful

Navigating The Complex Landscape Of Lentiviral Vector Quality Control

Meet The Experts: Part 1 - Process Analytical Technology (PAT)

Pioneering Solutions That Turn Hope Into Reality

Manufacturing Life-Saving Gene Therapies

FUJIFILM Biotechnologies Capabilities Update September 2026: Fill/Finish

Advancing Sterile Fill-Finish For Injectable Therapies

Resilience Capabilities Update July 2026: Fill/Finish

Rentschler Biopharma Capabilities Update July 2026: Large Molecule

Avid Bioservices Capabilities Update July 2026: Large Molecule

Samsung Biologics Capabilities Update July 2026: Large Molecule

Thermo Fisher Scientific Capabilities Update July 2026: Fill/Finish

KBI BioPharma Capabilities Update July 2026: Large Molecule

AbbVie Capabilities Update July 2026: Large Molecule

Pace Life Sciences Capabilities Update July 2026: Fill/ Finish

Ardena Capabilities Update July 2026: Fill/Finish

Resilience Capabilities Update May 2026: Large Molecule

Discovering A Unique Multimillion Euro Nanotechnology Facility

Bio4C ProcessPad™ Product Overview

Automated Bioburden Testing Solution

Biopharmaceuticals Development And Manufacturing: Wide-Ranging Expertise And Vertically Integrated Service

Introducing The MAST® Autosampling Solution

Targeting The Fast Lane With Optimized Viral Detection

Meet The Experts: Part 3 - Chemometrics And Model Building

CHO Fed-batch Portfolio: Cellvento® And EX-CELL® Advanced Media And Feeds

Meet The Experts: Part 1 - Process Analytical Technology (PAT)

MilliporeSigma Bio-Expo Live 2024: Upstream Bioprocessing

Real-Time Monitoring And Automated Sampling For Enhanced Efficiency

New Protein A Device Set To Redefine Biomanufacturing

Your CDMO Quality Oversight Is Not Working

The Minimum Package A CDMO Needs To See

Repeating An Experiment Is Not Quality Control

When Is It Too Early To Engage A CDMO?

The Missing Data That Can Send A Program Back To The Bench

CDMO Readiness Is More Than A Data Package

Charting A Direct Pathway From Academia To CDMOs

Match The CDMO To The Stage Of Development

Are You Really Ready To Transfer?

The Data Package Blind Spots That Create Surprises

Tech Transfer Is Not A Handoff

Tech Transfer Is More Than A Batch Record

Minimizing Particulate Risk

Selecting A CDMO: A Guide To Successful Collaboration

Fostering CDMO Collaboration On Both Sides

Streamline Your Path To Clinical Fill

Visionary Thinkers And Problem Solvers: The Cambrex Team

Annex 1 FAQs: How Is Behavior Changing As A Result Of EU GMP Annex 1?

Annex 1 FAQs: What Was The Biggest Challenge With EU GMP Annex 1?

Start With An Integrated, Verified PFS System

Delivering Top Quality Fill Finish Manufacturing

Annex 1 FAQs: Why Is A Good Supplier Partnership Pivotal To Meet Regulatory Expectations?

Collaborating To Craft Efficient Processes

Consistent, Reliable, High-Quality Components

Efficient, Single-Source PFS Supply

Managing Multiple Partners – And Materials – From Around The Globe

Protecting Your Drug Product

Planning For Scale-Up

Annex 1 FAQs: How Are We Responding To Provide Confidence For Customers?

Start Packaging Development Early

Annex 1 FAQs: How Do You Understand Risk Regarding Contamination Control?

Redefining Prefillable Syringe System

Workforce Challenges Key To Outsourcing

Annex 1 FAQs: How Are We Responding To Foster Trust With Customers?

Annex 1 FAQs: Responding To The 2022 Revision

Accountability For The Whole PFS System

Establishing A Container Closure System

Translating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D.

Bioprinting 3D Human Tissue To Discover And Test New Treatments With Viscient Bio's Keith Murphy

Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.

AI, China, And Biotech Investing With SR One's Simeon George, M.D.

Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding

Growing And Scaling A Radiopharmaceuticals Company With AdvanCell's Philina Lee, Ph.D.

Finding New Opportunities In Obesity With Moonwalk Bioscience's Alex Aravanis, M.D., Ph.D.

Biotech Finance And Investor Update With Independent Board Director Allan Shaw

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka

Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil

Getting To A First Product Approval With Celcuity's Brian Sullivan

Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings

A Rescue Model For Shelved Drug Candidates With Annette Bakker, Ph.D. And Andrew Lo, Ph.D.

Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D.

Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.

Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.

Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho

Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.

The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry

Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.

Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane

Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D.

Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.

From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.

Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary

The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw

Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.

Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor

Investing In Early-Stage Oncology With Yosemite's Dan McHugh

Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash

Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.

Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.

Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.

An Anthropological Lens On Leadership In Life Sciences With Bunka's Monika Sumra, Ph.D.

Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer

Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie

BoB@JPM: Brian Hilberdink, Boehringer Ingelheim

BoB@JPM: Ron Cooper, enGene

BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics

A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith

Life Science Connect Editors' Roundtable: Wrapping Up 2025 And Looking Ahead

Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos

Modernizing Clinical Trial Operations With Merck's Jennifer Sheller

Transforming Chronic Kidney Disease With ProKidney's Bruce Culleton, M.D.

Engineering B Cells With Immusoft's Sean Ainsworth

Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt

Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.

Biotech Funding And IPO Temperature Check With CREATE Medicine's Allan Shaw

Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier

Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D.

BoB in South Florida: Rich Daly, Catalyst Pharmaceuticals

BoB In South Florida: Anthony Japour, M.D., iTolerance

BoB In South Florida: Daniel Teper, NAYA Therapeutics

BoB In South Florida: Raquel Cabo, Miami Biotech Collective

The Business Case For Health Economics And Outcomes Research With ISPOR's Rob Abbott

Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham

Dye Drug Conjugates For Cancer With Lahjavida's Lyle Small

Investing In The Biostack With Modi Ventures' Sahir Ali, Ph.D.

Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D.

Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D.

Biotech Product Partnership with Coya Therapeutics' Arun Swaminathan, Ph.D. and Dr. Reddy's Milan Kalawadia

How To Hire And Build A Winning Executive Team With Occam Global's Bill Holodnak

The Generalist Biotech CEO With Seekyo's Oury Chetboun

Innovating On The Frontier Of Radiopharmaceuticals With RadioMedix's Ebrahim Delpassand, M.D.

Building An Efficient Biopharma With South Rampart Pharma's Hernan Bazan, M.D.

The Business And Science Of Obesity With Roger Cone, Ph.D., Founder Of Courage Therapeutics

BoB Live At BIO: Amber Salzman, Ph.D., Epicrispr Biotechnologies

How To Be A Policy Advocate For Biotech With NewYorkBIO's Jennifer Hawks Bland

FDA Trials And Tribulations With Connect Biopharma's Barry Quart

Proactive Procurement Strategies For Biotech With Tom Wells

The Discovery Of Microbes And Implications For Public Health Today, With Science Writer Thomas Levenson

Psychedelics For Mental Health Disorders With atai's Srinivas Rao, M.D., Ph.D.

Biotech Angel Investing With Yaniv Sneor

Leading A tRNA Startup With Alltrna's Michelle Werner

Executing A Product Pivot With Vir's Mark Eisner, MD

Commercializing RNAi Therapies With Alnylam's Tolga Tanguler

Big Pharma Insights For Building Biotech Startups With Uniquity Bio's Brian Lortie

The Implications Of China's Growing Biotech Industry With Allan Shaw

How To Be A CFO With Insmed's Sara Bonstein

Deal And Investment Trends With Investment Banker David Sans

Business of Biotech 2.0 with Ben Comer

BoB@JPM: Nima Farzan, Latigo Biotherapeutics

BoB@JPM: Kasper Roet, Ph.D., QurAlis

BoB@JPM: Rick Modi, Affinia Therapeutics

BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty

BoB@JPM: Tom Chalberg, Ph.D., Genascence

BoB@JPM: Ran Zheng, Landmark Bio

BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics

BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience

The Business Of CNS with Acumen's Jim Doherty, Ph.D.

High-Throughput Discovery With BIOPTIC's Andrey Dobry

RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D.

Biotech Story Time With Tal Zaks, M.D. (Part 2)

Risk Mitigation With MeiraGTx's Zandy Forbes, Ph.D.

Biotech Story Time With Tal Zaks, M.D. (Part 1)

A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D.

Manufacturing Partnership With Life Biosciences Jerry McLaughlin and Forge Biologics' John Maslowski

Advancing CGT Delivery, Regulatory Strategy with Axiom's Dr. Remo Moomiaie-Qajar

Advancing Cell Therapy Toward a Functional Cure for T1D With Forthcoming BetaNova's Jonathan Rigby and Will Rust, Ph.D.

Structuring CGT Deals for the Long Term with Troutman Pepper Locke's EA Weeks, J.D., Ph.D.

Shaping Drug Development by Starting with the Disease with Roche's Sylke Poehling, Ph.D.

Why Autoimmune CAR T Needs a New Patient-Centered Playbook with Dr. Panteli Theocharous

Reimagining Solid Tumor Immunotherapy Through Engineered Tregs with CoRegen's Dr. Sonal Gupta

Rewriting the Playbook for Stargardt Disease with Atsena Therapeutics' Shannon Boye, Ph.D.

How Precision Oncology Is Redefining Cancer Drug Development with Aprea Therapeutics' Dr. Oren Gilad

Exploring Dendritic Cell Therapy for Solid Tumors with Diakonos Oncology's Jay Hartenbach

Cell & Gene: The Podcast Presents: Better Biopharma's Editors' Roundtable — A Midyear Look at the 2026 Life Sciences Industry

Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers

Reimagining In Vivo Gene Editing Through Base Editing and Targeted Delivery with Beam Therapeutics' Gopi Shanker, Ph.D.